Search research articles
Contact Us
Filters
Showing results (401-410 of 536) with videos related to
Page
of 54
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 30, 2009
Acute myeloid leukemia
Margaret R O'Donnell, Frederick R Appelbaum, Steven E Coutre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Guido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Sebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Cell Stem Cell
|
May 14, 2020
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia
Chao Shen, Yue Sheng, Allen C Zhu, et al.
Blood
|
December 15, 2025
Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia
Lianjun Zhang, HyunJun Kang, Melissa Valerio, et al.
Transplantation and Cellular Therapy
|
August 5, 2024
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
Hany Elmariah, Salman Otoukesh, Ambuj Kumar, et al.
Blood Advances
|
December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Leukemia
|
December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
Susan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood
|
October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Guido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Page
of 54
Search research articles
Search
Showing results (401-410 of 536) with videos related to
Sort By:
Page
of 54
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 30, 2009
Acute myeloid leukemia
Margaret R O'Donnell, Frederick R Appelbaum, Steven E Coutre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Guido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Sebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Cell Stem Cell
|
May 14, 2020
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia
Chao Shen, Yue Sheng, Allen C Zhu, et al.
Blood
|
December 15, 2025
Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia
Lianjun Zhang, HyunJun Kang, Melissa Valerio, et al.
Transplantation and Cellular Therapy
|
August 5, 2024
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
Hany Elmariah, Salman Otoukesh, Ambuj Kumar, et al.
Blood Advances
|
December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Leukemia
|
December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
Susan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood
|
October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Guido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Page
of 54